Application of CRISPR/Cas9 Technology to HBV
More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...
Main Authors: | Guigao Lin, Kuo Zhang, Jinming Li |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/16/11/25950 |
Similar Items
-
Post-translational Modification Control of HBV Biological Processes
by: Fan Yang
Published: (2018-11-01) -
Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment
by: Xiaomei Wang, et al.
Published: (2021-01-01) -
Dynamics of HBV cccDNA expression and transcription in different cell growth phase
by: Chong Chin-Liew, et al.
Published: (2011-12-01) -
When Hepatitis B Virus Meets Interferons
by: Guangyun Tan, et al.
Published: (2018-07-01) -
Recent Advances in Hepatitis B Treatment
by: Georgia-Myrto Prifti, et al.
Published: (2021-05-01)